Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
Drug Costs
141-160 of 706 results
-
The Confusing Fate of the Abortion Pill
Episode 293The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
-
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
By Arthur Allen -
Journalists Delve Into Insulin Costs and Prior Authorization Policy
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.
By Arthur Allen -
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.
By Angela Hart -
Why Does Insulin Cost So Much? Big Pharma Isn’t the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
By Arthur Allen March Medicaid Madness
Episode 287President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts — leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
-
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
Eli Lilly's news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
By Bram Sable-Smith and Samantha Young -
California’s Massive Medicaid Program Works for Some, but Fails Many Others
Medi-Cal serves more than one-third of the state’s population — offering a dizzying range of care to a diverse population. In the new “Faces of Medi-Cal” series, California Healthline will assess the program’s strengths and weaknesses through the lives and experiences of its enrollees.
By Angela Hart and Bernard J. Wolfson -
After Capping Insulin Copays, Colorado Sets Its Sights on EpiPens
Colorado’s proposed legislation to cap the copay for the EpiPen is part of a nationwide trend as more states try to shield patients from skyrocketing drug prices.
-
A Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
-
Mark Cuban Has Been Taking On the Drug Industry. But Which One?
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
By Darius Tahir The Kids Are Not OK
Episode 285A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA’s 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
-
Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
By Fred Schulte A Health-Heavy State of the Union
Episode 284President Joe Biden’s 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
-
Centene Agrees to $215 Million Settlement With California for Alleged Medicaid Overbilling
The nation’s largest Medicaid insurer denies wrongdoing after the California attorney general’s office investigated it for inflating prescription drug costs.
-
Health Policies Were a Prominent Theme in Biden’s State of the Union Speech
Our partners at PolitiFact fact-checked a range of President Joe Biden’s statements, including key health-related comments.
-
‘We Ain’t Gonna Get It’: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.
By Arthur Allen -
Postcard From San Francisco
The Biggest, Buzziest Conference for Health Care Investors Convenes Amid Fears the Bubble Will Burst
This year’s JPMorgan confab, the first since covid’s chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
By Darius Tahir